A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC 66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma.

Trial Profile

A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC 66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2013

At a glance

  • Drugs Interferon alpha (Primary) ; Thalidomide (Primary)
  • Indications Follicular lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 11 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top